openPR Logo
Press release

Lyme Disease Diagnostic Market to Record an Exponential CAGR by 2019

07-05-2018 08:17 PM CET | Health & Medicine

Press release from: Transparency Market Research

Lyme Disease Diagnostic Market to Record an Exponential CAGR

Lyme disease is an infectious disease caused by bacterial species borrelia. It is a tick borne disease caused by the transmission to humans by the bite of infected ticks. Patients infected with lyme disease suffer from symptoms such as fever, depression, fatigue and skin rashes. If the disease is diagnosed at an early stage then it can be treated with antibiotics. However, if the disease is left untreated then it affects heart, joint and central nervous system and might become a cause for death.

The Lyme Disease Diagnostic Market is segmented on the basis of diagnostic tests, emerging diagnostic technologies and end users. Emerging technologies segment comprises of molecular diagnostics, monoclonal antibodies, immunoassays, differential light scattering, liposomes, artificial intelligence, flow cytometry, information technology, diagnostic imaging, gel microdroplets, chromatography and others. The endusers segment of the market includes hospitals, commercial/private labs, public health labs and physicians office. Various forms of laboratory testing for lyme disease are available and among them most widely used are serological test. Among the serological tests most commonly used are ELISA and Western Blot. Moreover, some laboratories offer tests that include urine antigen tests, lymphocytic transformation test, immunofluorescent staining and PCR tests. New lyme disease diagnostic tests are being developed that are particularly suited for diagnosis of chronic lyme infection using blood sample. These tests overcome the accuracy problems which were encountered in serology based tests.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1658

Globally North America accounts for the largest share of the market owing to the most common tick disease in the U.S. According to the Center for Disease Control and Prevention (CDC) in 2011, 24,364 people were diagnosed with lyme disease in the United States. The European and Asian markets are also expected to emerge in near future owing to increase in patients infected with lyme diseases.

Some of the key players engaged in manufacturing of diagnostic tests include Abbott Laboratories, Affymetrix, Inc., Bio-Rad, Roche Diagnostics among others.

View Report -

https://www.transparencymarketresearch.com/lyme-disease-diagnostic.html

About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lyme Disease Diagnostic Market to Record an Exponential CAGR by 2019 here

News-ID: 1112469 • Views:

More Releases from Transparency Market Research

Neuromorphic Chip Market to Reach USD 2.3 Billion by 2034, Driven by Explosive AI Adoption and Next-Generation Edge Computing Innovations | TMR
Neuromorphic Chip Market to Reach USD 2.3 Billion by 2034, Driven by Explosive A …
The global Neuromorphic Chip Market is entering a defining phase of exponential growth, propelled by a surge in artificial intelligence (AI) applications, edge computing expansion, and rapid advancements in next-generation semiconductor technologies. According to the latest industry analysis, the market-valued at US$ 56.2 Mn in 2023-is projected to expand at an extraordinary CAGR of 40.1% from 2024 to 2034, reaching an estimated US$ 2.3 Bn by 2034. Examine key highlights and
Neuroprotection Market Surges Toward USD 60.1 Bn by 2031 as Global Neurological Disease Burden Accelerates | TMR
Neuroprotection Market Surges Toward USD 60.1 Bn by 2031 as Global Neurological …
The global Neuroprotection Market continues to gain unprecedented momentum as healthcare systems worldwide intensify their focus on combating neurological disorders. With a valuation of US$ 31.6 Bn in 2022, the market is on track to reach US$ 60.1 Bn by 2031, expanding at a robust 7.5% CAGR during the forecast period. The rise in dementia, stroke, Parkinson's, epilepsy, and multiple sclerosis-combined with aging demographics and a surge in sedentary lifestyles-has
Neuroregeneration Therapy Market Set to Reach USD 64.8 Bn by 2034, Driven by Innovations in Gene Editing, Stem Cell Therapy, and AI-Based Neuromedicine | TMR
Neuroregeneration Therapy Market Set to Reach USD 64.8 Bn by 2034, Driven by Inn …
The global neuroregeneration therapy market continues to chart steady, sustained growth. The increasing incidence of neurological disorders-including Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, stroke, diabetic neuropathy, and spinal cord injuries-is significantly influencing market expansion. In 2023, the market was worth US$ 37.0 Bn, demonstrating rising demand for treatments capable of repairing or regenerating damaged neural tissue. Examine key highlights and takeaways from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86322 With breakthroughs
Neuroscience Market Set to Reach USD 41.6 Bn by 2031 Driven by Technological Advances in Brain Mapping, AI, and Portable Neuroimaging | TMR
Neuroscience Market Set to Reach USD 41.6 Bn by 2031 Driven by Technological Adv …
The global neuroscience market stood at US$ 30.1 Bn in 2022, reflecting the significant technological and clinical potential of neurological research. Projected to grow at a CAGR of 3.7% from 2023 to 2031, the industry is expected to reach US$ 41.6 Bn by 2031. Rising prevalence of neurodegenerative diseases, advancements in neuroimaging, integration of artificial intelligence, and the emergence of brain-computer interfaces are shaping the next decade of neuroscience innovation. Examine

All 5 Releases


More Releases for Lyme

Lyme Disease Diagnostics Market Projected to Show Strong Growth
Advance Market Analytics published a new research publication on "Lyme Disease Diagnostics Market Insights, to 2033" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Lyme Disease Diagnostics market was mainly driven by the increasing R&D spending across the world. Get Free Exclusive PDF Sample
Lyme Disease - Drug Pipeline Landscape, 2022
Lyme disease is a tick-borne infection caused by four main species of bacteria Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii and Borrelia garinii. The disease is characterized by skin rash. Early signs and symptoms of Lyme disease include rash and other symptoms like fever, chills, fatigue, body aches, and swollen lymph nodes. Later symptoms include erythema migrans, joint pain and other neurological problems. To know more about Lyme Disease - Drug Pipeline ,
Lyme Disease - Drug Pipeline Landscape, 2022 | Global Insight Services
Lyme disease is a tick-borne infection caused by four main species of bacteria Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii and Borrelia garinii. The disease is characterized by skin rash. Early signs and symptoms of Lyme disease include rash and other symptoms like fever, chills, fatigue, body aches, and swollen lymph nodes. Later symptoms include erythema migrans, joint pain and other neurological problems. Diagnosis of Lyme disease involves lab tests to
Lyme Disease Vaccines - Are They Effective?| Valneva, GlaxoSmithKline Plc.
There is currently no Lyme disease vaccine available. LYMERix®, the only vaccine previously marketed in the United States, was withdrawn from the market in 2002 due to a lack of consumer demand. The vaccine's effectiveness deteriorates over time. Lyme Disease Vaccines Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing
Lyme Disease Therapeutics Market Size Statistics, Facts and Figures
Global Lyme Disease Therapeutics Market: Overview Lyme disease is a contagious disease caused by a bacterium species called Borrelia burgdorferi. It is a tick-borne disease caused by transmission of bacteria to humans through the bite of infected ticks. Common indications of Lyme disease include flu-like symptoms, depression, fatigue, and expanding, circular, reddish skin rashes. View Report : https://www.transparencymarketresearch.com/lyme-disease-therapeutics-market.html If left untreated, these symptoms may worsen and can lead to partial or complete
Lyme Disease Diagnostic Testing Market
The report presents a detailed analysis of the Lyme disease diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Lyme disease definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Commercial/Private Labs